A low-fat, whole-food vegan diet, as well as other strategies that down-regulate IGF-I activity, may slow the human aging process

Medical Hypotheses

Volumn 60, Issue 6, 2003, Pages 784-792

  McCarty, Mark F ^a  

^a Pantox Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; CHROMIUM PICOLINATE; ESTROGEN; MANNAN; NITRIC OXIDE; SOMATOMEDIN C; TAMOXIFEN;

AGING; CALORIC RESTRICTION; DOG; ENDOMETRIUM CANCER; EXERCISE; FLAX; GENE MUTATION; HIGH FIBER DIET; HUMAN; INSULIN SENSITIVITY; LIFESPAN; LOW FAT DIET; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL MATURITY; SODIUM RESTRICTION; STROKE; VEGETABLE;

CANIS FAMILIARIS; LINUM USITATISSIMUM; MAMMALIA; RODENTIA;

EID: 0037410568     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00235-9     Document Type: Review

References (143)

1. Zhou Y., Xu B. C., Maheshwari H. G. et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci USA 1997; 94: 3215-3220.
2. Coschigano K. T., Clemmons D., Bellush L. L., Kopchick J. J. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000; 141: 2608-2613.
3. Kinney B. A., Coschigano K. T., Kopchick J. J., Steger R. W., Bartke A. Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiol Behav 2001; 72: 653-660.
4. Hauck S. J., Hunter W. S., Danilovich N., Kopchick J. J., Bartke A. Reduced levels of thyroid hormones, insulin, and glucose, and lower body core temperature in the growth hormone receptor/binding protein knockout mouse. Exp Biol Med (Maywood) 2001; 226: 552-558.
5. Sornson M., Wu W., Dasen J. S. et al. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996; 384: 327-333.
6. Brown-Borg H. M., Borg K. E., Meliska C. J., Bartke A. Dwarf mice and the aging process. Nature 1996; 384: 33.
7. Kinney B. A., Meliska C. J., Steger R. W., Bartke A. Evidence that Ames dwarf mice age differently from their normal siblings in behavioral and learning and memory parameters. Horm Behav 2001; 39: 277-284.
8. Li S., Crenshaw E. B., Rawson E. J., Simmons D. M., Swanson L. W., Rosenfeld M. G. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990; 347: 528-533.
9. Miller R. A. Kleemeier award lecture: are there genes for aging? J Gerontol A Biol Sci Med Sci 1999; 54: B297-B307.
10. Flurkey K., Papaconstantinou J., Miller R. A., Harrison D. E. Lifespan extension and delayed immune and collagen aging in mutant mice with defects in growth hormone production. Proc Natl Acad Sci USA 2001; 98: 6736-6741.
11. Bartke A., Coschigano K., Kopchick J. et al. Genes that prolong life: relationships of growth hormone and growth to aging and life span. J Gerontol A Biol Sci Med Sci 2001; 56: B340-B349.
12. Migliaccio E., Giorgio M., Mele S. et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313.
13. Lithgow G. J., Andersen J. K. The real Dorian Gray mouse. Bioessays 2000; 22: 410-413.
14. Breese C. R., Ingram R. L., Sormtag W. E. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J Gerontol 1991; 46: B180-B187.
15. Oster M. H., Fielder P. J., Levin N., Cronin M. J. Adaptation of the growth hormone and insulin-like growth factor-I axis to chronic and severe calorie or protein malnutrition. J Clin Invest 1995; 95: 2258-2265.
16. Dunn S. E., Kari F. W., French J. et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57: 4667-4672.
17. Sonntag W. E., Lynch C. D., Cefalu W. T. et al. Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. J Gerontol A Biol Sci Med Sci 1999; 54: B521-B538.
18. Masoro E. J. Antiaging action of caloric restriction: endocrine and metabolic aspects. Obes Res 1995; 3(Suppl 2): 241s-247s.
19. Masoro E. J. Caloric restriction and aging: an update. Exp Gerontol 2000; 35: 299-305.
20. Dhahbi J. M., Mote P. L., Wingo J. et al. Caloric restriction alters the feeding response of key metabolic enzyme genes. Mech Aging Dev 2001; 122: 1033-1048.
21. Lewitt M. S., Baxter R. C. Insulin-like growth factor-binding protein-1: a role in glucose counterregulation? Mol Cell Endocrinol 1991; 79: C147-C152.
22. Baxter R. C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994; 42: 140-144.
23. Frystyk J., Hussain M., Skjaerbaek C. et al. Serum free IGF-I during a hyperinsulinemic clamp following 3 days of administration of IGF-I vs. saline. Am J Physiol 1997; 273: E507-E513.
24. Kari F. W., Dunn S. E., French J. E., Barren J. C. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging 1999; 3: 92-101.
25. Underwood L. E., Thissen J. P., Lemozy S., Ketelslegers J. M., Clemmons D. R. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145-151.
26. Straus D. S. Nutritional regulation of hormones and growth factors that control mammalian growth. FASEB J 1994; 8: 6-12.
27. Orentreich N., Matias J. R., De Felice A., Zimmerman J. A. Low methionine ingestion by rats extends life span. J Nutr 1993; 123: 269-274.
28. Richie J. P. J., Leutzinger Y., Parthasarathy S., Malloy V., Orentreich N., Zimmerman J. A. Methionine restriction increases blood glutathione and longevity in F344 rats. FASEB J 1994; 8: 1302-1307.
29. Segall P. E., Timiras P. S. Patho-physiologic findings after chronic tryptophan deficiency in rats: a model for delayed growth and aging. Mech Aging Dev 1976; 5: 109-124.
30. Ooka H., Segall P. E., Timiras P. S. Histology and survival in age-delayed low-tryptophan-fed rats. Mech Aging Dev 1988; 43: 79-98.
31. Patronek G. J., Waters D. J., Glickman L. T. Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 1997; 52: B171-B178.
32. Michell A. R. Longevity of British breeds of dog and its relationships with sex, size, cardiovascular variables, and disease. Vet Rec 1999; 145: 625-629.
33. Eigenmann J. E., Patterson D. F., Zapf J., Froesch E. R. Insulin-like growth factor I in the dog: a study in different dog breeds and in dogs with growth hormone elevation. Acta Endocrinol (Copenh) 1984; 105: 294-301.
34. Eigenmann J. E., Patterson D. F., Froesch E. R. Body size parallels insulin-like growth factor I levels but not growth hormone secretory capacity. Acta Endocrinol (Copenh) 1984; 106: 448-453.
35. Eigenmann J. E., Amador A., Patterson D. F. Insulin-like growth factor I levels in proportionate dogs, chondrodystrophic dogs, and in giant dogs. Acta Endocrinol (Copenh) 1988; 118: 105-108.
36. Eklund J., Bradford G. E. Longeveity and lifetime body weight in mice selected for rapid growth. Nature 1977; 265: 48-49.
37. Miller R. A., Chrisp C., Atchley W. Differential longevity in mouse stocks selected for early life growth trajectory. J Gerontol A Biol Sci Med Sci 2000; 55: B455-B461.
38. Evans G. W., Meyer L. K. Life span is increased in rats supplemented with a chromium-pyridine-2-carboxylate complex. Adv Sci Res 1994; 1: 19-23.
39. Dilman V. M., Anisimov V. N. Effect of treatment with phenformin, diphenylhydantoin, or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology 1980; 26: 241-246.
40. Kenyon C. A conserved regulatory system for aging. Cell 2001; 105: 165-168.
41. Gems D., Partridge L. Insulin/IGF signalling and aging: seeing the bigger picture. Curr Opin Genet Dev 2001; 11: 287-292.
42. Bartke A. Mutations prolong life in flies; implications for aging in mammals. Trends Endocrinol Metab 2001; 12: 233-234.
43. Clancy D. J., Gems D., Harshman L. G. et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001; 292: 104-106.
44. Fabrizio P., Pozza F., Pletcher S. D., Gendron C. M., Longo V. D. Regulation of longevity and stress resistance by Sch9 in yeast. Science 2001; 292: 288-290.
45. Parr T. Insulin exposure controls the rate of mammalian aging. Mech Aging Dev 1996; 88: 75-82.
46. Parr T. Insulin exposure and aging theory. Gerontology 1997; 43: 182-200.
47. McCarty M. F. Dietary glycemic index may influence cancer risk by modulating IGF-I activity: a hypothesis. J Med Food 1998; 1: 123-140.
48. Hiney J. K., Ojeda S. R., Dees W. L. Insulin-like growth factor I: a possible metabolic signal involved in the regulation of female puberty. Neuroendocrinology 1991; 54: 420-423.
49. Nobels F., Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992; 58: 655-666.
50. Mauras N., Rogol A. D., Haymond M. W., Veldhuis J. D. Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine, and metabolic regulation in puberty. Horm Res 1996; 45: 74-80.
51. Hiney J. K., Srivastava V., Nyberg C. L., Ojeda S. R., Dees W. L. Insulin-like growth factor I of peripheral origin acts centrally to accelerate the initiation of female puberty. Endocrinology 1996; 137: 3717-3728.
52. Wilson M. E. IGF-I administration advances the decrease in hypersensitivity to oestradiol negative feedback inhibition of serum LH in adolescent female rhesus monkeys. J Endocrinol 1995; 145: 121-130.
53. Okasha M., McCarron P., McEwen J., Smith G. D. Age at menarche: secular trends and association with adult anthropometric measures. Ann Hum Biol 2001; 28: 68-78.
54. Graham M. J., Larsen U., Xu X. Secular trend in age at menarche in China: a case study of two rural countries in Anhui Province. J Biosoc Sci 1999; 31: 257-267.
55. Migliaccio E., Mele S., Salcini A. E. et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997; 16: 706-716.
56. Butler A. A., Yakar S., Gewolb I. H., Karas M., Okubo Y., LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 1998; 121: 19-26.
57. Masoro E. J., McCarter R. J., Katz M. S., McMahan C. A. Dietary restriction alters characteristics of glucose fuel use [published erratum appears in J Gerontol 1993 Mar:48 (2):B73] J Gerontol 1992; 47: B202-B208.
58. McCarty M. F. Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity [In Process Citation] Med Hypotheses 1999; 53: 459-485.
59. McCarty M. F. Mortality from Western cancers rose dramatically among African-Americans during the 20th century: are dietary animal products to blame. Med Hypotheses Century 2001; 57: 169-174.
60. McCarty M. F. The origins of western obesity; a role for animal protein? Med Hypotheses 2000; 54: 488-494.
61. Campbell T. C., Chen J. Energy balance: interpretation of data from rural China. Toxicol Sci 1999; 52: 87-94.
62. Ornish D. Eat More, Weigh Less: Dr. Dean Ornish's Life Choice Program for Losing Weight Safely While Eating Abundantly. New York: Harper, 1997.
63. Barnard R. J., Ugianskis E. J., Martin D. A., Inkeles S. B. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am J Cardiol 1992; 69: 440-444.
64. Fukagawa N. K., Anderson J. W., Hageman G., Young V. R., Minaker K. L. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr 1990; 52: 524-528.
65. Rabinowitz D., Merimee T. J., Maffezzoli R., Burgess J. A. Patterns of hormonal release after glucose, protein, and glucose plus protein. Lancet 1966; 2: 454-456.
66. Warren R. S., Yuan H., Matli M. R., Ferrara N., Donner D. B. Induction of vascular endothelial growth factor by insulin-like growth factor1 in colorectal carcinoma. J Biol Chem 1996; 271: 29483-29488.
67. Straus D. S., Burke E. J., Marten N. W. Induction of insulin-like growth factor binding protein-1 gene expression in liver of protein-restricted rats and in rat hepatoma cells limited for a single amino acid. Endocrinology 1993; 132: 1090-1100.
68. Allen N. E., Appleby P. N., Davey G. K., Key T. J. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer 2000; 83: 95-97.
69. van Dusseldorp M., Arts I. C., Bergsma J. S., De Jong N., Dagnelie P. C., van Staveren W. A. Catch-up growth in children fed a macrobiotic diet in early childhood. J Nutr 1996; 126: 2977-2983.
70. Yu H., Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489.
71. Sacks F. M., Castelli W. P., Donner A., Kass E. H. Plasma lipids and lipoproteins in vegetarians and controls. N Engl J Med 1975; 292: 1148-1151.
72. Sacks F. M., Rosner B., Kass E. H. Blood pressure in vegetarians. Am J Epidemiol 1974; 100: 390-398.
73. Barnard R. J. Effects of life-style modification on serum lipids. Arch Intern Med 1991; 151: 1389-1394.
74. Mehrabian M., Peter J. B., Barnard R. J., Lusis A. J. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990; 84: 25-32.
75. Ornish D., Brown S. E., Scherwitz L. W. et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial [see comments]. Lancet 1990; 336: 129-133.
76. Barnard R. J., Jung T., Inkeles S. B. Diet and exercise in the treatment of NIDDM. The need for early emphasis. Diabetes Care 1994; 17: 1469-1472.
77. Skov A. R., Toubro S., Ronn B., Holm L., Astrup A. Randomized trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. Int J Obes Relat Metab Disord 1999; 23: 528-536.
78. Hannah J. S., Dubey A. K., Hansen B. C. Postingestional effects of a high-protein diet on the regulation of food intake in monkeys. Am J Clin Nutr 1990; 52: 320-325.
79. Howarth N. C., Saltzman E., Roberts S. B. Dietary fiber and weight regulation. Nutr Rev 2001; 59: 129-139.
80. Astrup A. The role of dietary fat in the prevention and treatment of obesity. Efficacy and safety of low-fat diets. Int J Obes Relat Metab Disord 2001; 25(Suppl 1): S46-S50.
81. Ludwig D. S., Majzoub J. A., Al-Zahrani A., Dallal G. E., Blanco I., Roberts S. B. High glycemic index foods, overeating, and obesity. Pediatrics 1999; 103: E26.
82. Spieth L. E., Hamish J. D., Lenders C. M. et al. A low-glycemic index diet in the treatment of pediatric obesity. Arch Pediatr Adolesc Med 2000; 154: 947-951.
83. Duncan K. H., Bacon J. A., Weinsier R. L. The effects of high and low energy density diets on satiety, energy intake, and eating time of obese and non-obese subjects. Am J Clin Nutr 1983; 37: 763-767.
84. Shintani T. T., Hughes C. K., Beckham S., O'Connor H. K. Obesity and cardiovascular risk intervention through the ad libitum feeding of traditional Hawaiian diet. Am J Clin Nutr 1991; 53: 1647S-1651S.
85. Vita P. M., Restelli A., Caspani P., Klinger R. Chronic use of glucomannan in the dietary treatment of severe obesity. Minerva Med 1992; 83: 135-139.
86. Livieri C., Novazi F., Lorini R. The use of highly purified glucomannan-based fibers in childhood obesity. Pediatr Med Chir 1992; 14: 195-198.
87. Cairella M., Marchini G. Evaluation of the action of glucomannan on metabolic parameters and on the sensation of satiation in overweight and obese patients. Clin Ter 1995; 146: 269-274.
88. Walsh D. E., Yaghoubian V., Behforooz A. Effect of glucomannan on obese patients: a clinical study. Int J Obes 1984; 8: 289-293.
89. Anchors M. Fluoxetine is a safer altemative to fenfluramine in the medical treatment of obesity [letter]. Arch Intern Med 1997; 157: 1270.
90. Miskin R., Masos T. Transgenic mice overexpressing urokinase-type plasminogen activator in the brain exhibit reduced food consumption, body weight and size, and increased longevity. J Gerontol A Biol Sci Med Sci 1997; 52: B118-B124.
91. Anderson R. A., Cheng N., Bryden N. A., Polansky M. M., Chi J., Feng J. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997; 46: 1786-1791.
92. Cefalu W. T., Bell-Farrow A. D., Wang Z. Q. et al. The effect of chromium supplementation on carbohydrate metabolism and body composition. Diabetes 1997; 46(Suppl 1): 55A.
93. Lebovitz H. E., Banerji M. A. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 1901; 56: 265-294.
94. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J. E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus [see comments] N Engl J Med 1995; 333: 550-554.
95. McCarty M. F. High-dose biotin, an inducer of glucokinase expression, may synergize with chromium picolinate to enable a definitive nutritional therapy for type 2 diabetes. Med Hypotheses 1999; 52: 401-406.
96. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr 1995; 49(Suppl 3): S190-S197.
97. Anderson J. W., Allgood L. D., Turner J., Oeltgen P. R., Daggy B. P. Effects of psyllium on glucose and serum lipid responses in men with type 2 diabetes and hypercholesterolemia. Am J Clin Nutr 1999; 70: 466-473.
98. Ou S., Kwok K., Li Y., Fu L. In vitro study of possible role of dietary fiber in lowering postprandial serum glucose. J Agric Food Chem 2001; 49: 1026-1029.
99. Ebihara K., Nakajo S. Effect of acetic acid and vinegar on blood glucose and insulin responses to orally administered sucrose and starch. Agric Biol Chem 1988; 52: 1311-1312.
100. Liljeberg H., Bjorck I. Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar. Eur J Clin Nutr 1998; 52: 368-371.
101. Brighenti F., Castellani G., Benini L. et al. Effect of neutralized and native vinegar on blood glucose and acetate responses to a mixed meal in healthy subjects. Eur J Clin Nutr 1995; 49: 242-247.
102. Rickard S. E., Yuan Y. V., Thompson L. U. Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flaxseed or its lignan secoisolariciresinol diglycoside. Cancer Lett 2000; 161: 47-55.
103. Campagnoli C., Biglia N., Peris C., Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995; 9: 67-74.
104. Helle S. I., Omsjo I. H., Hughes S. C. et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3 across-over study. Clin Endocrinol (Oxf) 1996; 45: 727-732.
105. Paassilta M., Karjalainen A., Kervinen K. et al. Insulin-like growth factor binding protein-1 (IGFBP-1) and IGF-I during oral and transdermal estrogen replacement therapy relation to lipoprotein(a) levels. Atherosclerosis 2000; 149: 157-162.
106. Decensi A., Robertson C., Ballardini B. et al. Effect of tamoxifen on lipoprotein(a) and insulin-like growth factor-I (IGF-I) in healthy women. Eur J Cancer 1999; 35: 596-600.
107. Corsello S. M., Rota C. A., Putignano P. et al. Effect of acute and chronic administration of tamoxifen on GH response to GHRH and on IGF-I serum levels in women with breast cancer. Eur J Endocrinol 1998; 139: 309-313.
108. McCarty M. F. Concurrent administration of sustained-release bezafibrate may counteract the increased thrombotic risk associated with oral estrogen therapy. Med Hypotheses 2001; 57: 216-220.
109. White I. N. Anti-oestrogenic drugs and endometrial cancers. Toxicol Lett 2001; 120: 21-29.
110. Thompson L. U., Seidl M. M., Rickard S. E., Orcheson L. J., Fong H. H. Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 1996; 26: 159-165.
111. Jenab M., Thompson L. U. The influence of flaxseed and lignans on colon carcinogenesis and beta-glucuronidase activity. Carcinogenesis 1996; 17: 1343-1348.
112. Thompson L. U., Rickard S. E., Orcheson L. J., Seidl M. M. Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 1996; 17: 1373-1376.
113. Thompson L. U. Experimental studies on lignans and cancer. Baillieres Clin Endocrinol Metab 1998; 12: 691-705.
114. Yan L., Yee J. A., Li D., McGuire M. H., Thompson L. U. Dietary flaxseed supplementation and experimental metastasis of melanoma cells in mice. Cancer Lett 1998; 124: 181-186.
115. Michell B. J., Griffiths J. E., Mitchelhill K. I. et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol 1999; 9: 845-848.
116. Isenovic E., Muniyappa R., Milivojevic N., Rao Y., Sowers J. R. Role of PI3-kinase in isoproterenol and IGF-1 induced ecNOS activity. Biochem Biophys Res Commun 2001; 285: 954-958.
117. Boger R. H. Nitric oxide and the mediation of the hemodynamic effects of growth hormone in humans. J Endocrinol Invest 1999; 22: 75-81.
118. Pfeifer M., Verhovec R., Zizek B., Prezelj J., Poredos P., Clayton R. N. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 453-457.
119. Conn K. J., Rich C. B., Jensen D. E. et al. Insulin-like growth factor-I regulates transcription of the elastin gene through a putative retinoblastoma control element. A role for Sp3 acting as a represser of elastin gene transcription. J Biol Chem 1996; 271: 28853-28860.
120. Bayes-Genis A., Conover C. A., Schwartz R. S. The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res 2000; 86: 125-130.
121. Lim M. J., Barkan A. L., Buda A. J. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117: 719-726.
122. Rosen T., Bengtsson B. A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285-288.
123. Bulow B., Hagmar L., Mikoczy Z., Nordstrom C. H., Erfurth E. M. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997; 46: 75-81.
124. Pfeifer M., Verhovec R., Zizek B. Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment. Growth Horm IGF Res 1999; 9(Suppl A): 25-30.
125. Colao A., Marzullo P., Di Somma C., Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001; 54: 137-154.
126. Abdu T. A., Neary R., Elhadd T. A., Akber M., Clayton R. N. Coronary risk in growth hormone deficient hypopituitary adults increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol (Oxf) 2001; 55: 209-216.
127. Samaras T. T., Elrick H., Storms L. H. Height, health, and growth hormone. Acta Paediatr 1999; 88: 602-609.
128. Waaler H. T. Height, weight, and mortality. The Norwegian experience. Acta Med Scand Suppl 1984; 679: 1-56.
129. Marmot M. G., Shipley M. J., Rose G. Inequalities in death-specific explanations of a general pattern? Lancet 1984; 1: 1003-1006.
130. Barker D. J., Osmond C., Golding J. Height and mortality in the countries of England and Wales. Ann Hum Biol 1990; 17: 1-6.
131. Jorgensen J. O., Vahl N., Fisker S. et al. Somatopause and adiposity. Horm Res 1997; 48(Suppl 5): 101-104.
132. Reed D. M. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990; 131: 579-588.
133. Yamori Y., Kihara M., Fujikawa J. et al. Dietary risk factors of stroke and hypertension in Japan - Part 3 Comparative study on risk factors between farming and fishing villages in japan. Jpn Circ J 1982; 46: 944-947.
134. Yamori Y., Horie R., Tanase H., Fujiwara K., Nara Y., Lovenberg W. Possible role of nutritional factors in the incidence of cerebral lesions in stroke-prone spontaneously hypertensive rats. Hypertension 1984; 6: 49-53.
135. Lindeberg S., Lundh B. Apparent absence of stroke and ischaemic heart disease in a traditional Melanesian island a clinical study in Kitava. J Intern Med 1993; 233: 269-275.
136. McCarty M. F. Up-regulation of endothelial nitric oxide activity as a central strategy for prevention of ischemic stroke-just say NO to stroke!. Med Hypotheses 2000; 55: 386-403.
137. Endres M., Laufs U., Huang Z. et al. Stroke protection by 3-hydroxy-3-methylglutaryl HMG-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-8885.
138. Kleinert H., Wallerath T., Euchenhofer C., Ihrig-Biedert I., Li H., Forstermann U. Estrogens increase transcription of the human endothelial NO synthase gene: analysis of the transcription factors involved. Hypertension 1998; 31: 582-588.
139. McCarty M. F. Policosanol safely down-regulates HMG-CoA reductase - potential as a component of the Esselstyn regimen. Med Hypotheses 2001; submitted for publication.
140. Jyung R. W., Mustoe J. A., Busby W. H., Clemmons D. R. Increased wound-breaking strength induced by insulin-like growth factor I in combination with insulin-like growth factor binding protein-1. Surgery 1994; 115: 233-239.
141. Bitar M. S. Insulin-like growth factor-1 reverses diabetes-induced wound healing impairment in rats. Horm Metab Res 1997; 29: 383-386.
142. Reed M. J., Penn P. E., Li Y. et al. Enhanced cell proliferation and biosynthesis mediate improved wound repair in refed, caloric-restricted mice. Mech Aging Dev 1996; 89: 21-43.
143. Friedlander A. L., Butterfield G. E., Moynihan S. et al. One year of insulin-like growth factor 1 treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1496-1503.